Rankings
▼
Calendar
NVAX FY 2025 Earnings — Novavax, Inc. Revenue & Financial Results | Market Cap Arena
NVAX
Novavax, Inc.
$2B
FY 2025 Earnings
Healthcare
Biotechnology
Income Statement
Revenue
$1.1B
+64.7% YoY
Gross Profit
$1.1B
93.7% margin
Operating Income
$563M
50.1% margin
Net Income
$440M
39.2% margin
EPS (Diluted)
$2.54
Cash Flow
Operating Cash Flow
-$245M
Free Cash Flow
-$250M
Stock-Based Comp.
$36M
Balance Sheet
Total Assets
$1.2B
Total Liabilities
$1.3B
Stockholders' Equity
-$128M
Cash & Equivalents
$241M
Year-over-Year Comparison
Metric
Current
Year Ago
Change
Revenue
$1.1B
$682M
+64.7%
Gross Profit
$1.1B
$479M
+119.5%
Operating Income
$563M
-$249M
+326.3%
Net Income
$440M
-$187M
+334.8%
← Q4 2024
All Quarters
Q1 2025 →